About St. RenatusSt. Renatus, LLC was founded to commercialize and distribute a revolutionary innovation – the world’s first dental anesthetic administered through the nasal cavity and suitable for use in procedures involving most of the upper teeth. The company’s name comes from the patron saint of anesthesia and has Latin roots meaning new beginning. St. Renatus believes the benefits of our product will provide a better experience for doctors and qualifying patients. These benefits include an accurate and sophisticated method to anesthetize the upper teeth topically, without the risk, fear, and pain of an injection. Patients do not experience the uncomfortable cheek or “fat lip” numbness associated with the needle. Executive Team
Steven T. Merrick
Mr. Merrick joined the St. Renatus team in September 2009. As the chief executive officer, he oversees all operations to help fund, complete the FDA process, commercialize, and distribute the new drug. Prior to joining St. Renatus, Mr. Merrick was with Septodont, the world’s leading provider of injectable dental anesthetic for over 15 years. There, he served as the vice president of global marketing for the Pain Control Division. In previous years at the company, Mr. Merrick also held positions as vice president of marketing, anesthetic marketing director, anesthetic product manager, and the mid-Atlantic sales representative. During his tenure, he was involved in the FDA approval process for a variety of local anesthetics including the best selling branded anesthetic in dentistry. Mr. Merrick holds a B.A. in marketing from Rider University in Lawrenceville, New Jersey. Mr. Merrick currently lives in Pennsylvania with his wife and three children. Jill M. Shoemaker, M.B.A. Ms. Shoemaker has been with St. Renatus since its inception in 2008. Prior to becoming vice president of investor relations, she served as St. Renatus’ director of finance. Ms. Shoemaker helps St. Renatus develop new sources of capital and foster relationships with prospective investors. Formerly, Ms. Shoemaker was a financial advisor with Merrill Lynch. She has eight years of securities and investor management experience. Ms. Shoemaker received a B.A. in fine arts from The College of Wooster and an M.B.A. from Malone College. Paul G. Sletten, D.D.S. Dr. Sletten joined the St. Renatus team in March of 2009. As the director of Scientific and Clinical Affairs, Dr. Sletten is coordinates scientific and clinical projects related to the FDA Phase 3 clinical process with Mr. Merrick, Dr. Kollar, and the Scientific Advisory Board. Dr. Sletten worked as a restorative dentist in the University of Minnesota Community Health Care System until moving into private practice, where he has worked and studied with groups on an international level. Dr. Sletten is devoting his full attention to St. Renatus. Sandra Brown, Ph.D Dr. Brown joined St. Renatus, LLC on May 1, 2010. As Director of Technical Affairs, Dr. Brown will oversee manufacturing and regulatory issues surrounding the production and ongoing stability studies of our nasal mist product development. Dr. Brown has more than 25 years experience as a consultant to pharmaceutical firms preparing Investigational (IND) and New Drug (NDA) applications and assisting in readiness for undergoing FDA inspections of manufacturing facilities, with participation in obtaining approvals for more than 20 new drug products. Prior to becoming a consultant, Dr. Brown was a chemistry reviewer for new drugs at FDA and worked in the chemical manufacturing industry. Board of DirectorsCliff M. Buchholz A successful entrepreneur, Mr. Buchholz is the owner of Miramont Lifestyle Fitness in Fort Collins, Colorado. Until 2002, he was also co-owner of the Sony Ericsson Open. From March to September 2009, Mr. Buchholz served as St. Renatus’ interim chief executive officer. Martin A. Culhane, III Mr. Culhane is an attorney and partner with Oppenheimer Wolff and Donnelly, LLP in Minneapolis, Minnesota, with a specialization in tax law. He is licensed as a certified public accountant with extensive experience in the areas of corporate mergers and acquisitions, partnerships, tax planning and analysis, as well as state, local, and international tax matters.
Ronald W. Hart, Ph.D. Dr. Ronald W. Hart has served on the editorial boards of more than a dozen professional journals and authored and co-authored over 650 scientific and managerial publications. Dr. Hart is the former Director of the National Center for Toxicological Research. He is the co-author of the Technology Transfer Act of 1986, which has resulted in the estimated creation of over 70,000 corporations and 8 million new jobs. He also served as the advisor to the White House Office of Science and Technology Policy, a chair of a number of White House and US Department of Health and Human Services (DHHS) commissions and task forces, chair of the US-USSR Emerging Leaders Conference, Science and Technology Section, and first co-chair of the Intergovernmental Task Force on Technology Transfer.
Mark D. Kollar, D.D.S. Dr. Kollar currently serves as a senior advisor to St. Renatus, managing projects that relate to FDA market approval and intellectual property. An assistant professor of restorative science at the University of Minnesota for eight years, Dr. Kollar was in a private dental practice for 23 years before devoting his full attention to developing the St. Renatus nasal mist.
Steven T. Merrick
James P. Mulvahill Mr. Mulvahill currently serves as a senior advisor to St. Renatus, managing projects that relate to FDA market approval and intellectual property. Until 2005, Mr. Mulvahill practiced as an attorney in the area of business and health law, with a heavy emphasis on representing medical and dental practices. Frank R. Ramirez As Chief Executive Officer of Ice Energy, an energy technology company in Windsor, Colorado, Mr. Ramirez was a founder and managing member of CES LLC, an innovative energy solutions company for mission critical facilities, as well as the founder and former managing director of Structured Capital Management. Mr. Ramirez began his career as a staff attorney for the U.S. Securities and Exchange Commission in Washington, D.C. He is a former principal of Alex Brown and Sons, as well as a former managing director of Bear, Stearns & Co, Inc. Christopher M. Scotti Mr. Scotti is an attorney and partner with Oppenheimer Wolff and Donnelly LLP, specializing in all aspects of commercial and consumer finance transactions, as well as compliance and general business counseling and transactions. Eric F. Stoer Mr. Stoer was a member of the Board of Directors of Boehringer Mannheim Pharmaceuticals Corporation, and formally chairman of the board of FASgen, Inc., a pharmaceutical company formed in 2000 as a spin-off from The Johns Hopkins University. Mr. Stoer has provided consultation for the successful U.S. approval of numerous drugs, three of which each had over $1.0 billion in annual sales.
Scientific Advisory Board
Sebastian G. Ciancio, D.D.S.
Stanley F. Malamed, D.D.S.
John A. Yagiela, Ph.D., D.D.S. |
|
